Insider Shareholders with Direct Ownership of Oncternal Therapeutics, Inc. (ONCT)
This section provides a comprehensive overview of the insiders with direct ownership of Oncternal Therapeutics, Inc. (ONCT). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Oncternal Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
James B Breitmeyer
Chief Executive Officer |
314,182 | 126,740 | 569,774 $649,542 | 5 |
Jul 28, 2022
Added 24.57%
|
|
Richard G Vincent
Chief Financial Officer |
120,492 | 20,365 | 140,922 $160,651 | 11 |
Jan 03, 2024
Reduced 5.92%
|
|
Salim Yazji
Chief Medical Officer |
174,637 | 46,002 | 128,635 $146,643 | 9 |
Jan 03, 2024
Reduced 13.31%
|
|
Gunnar F. Kaufmann
Chief Scientific Officer |
100,992 | 6,266 | 94,726 $107,987 | 5 |
Jun 14, 2023
Added 3.07%
|
|
Chase C. Leavitt
General Counsel/Secretary |
112,992 | 28,234 | 84,758 $96,624 | 10 |
Jan 03, 2024
Reduced 12.26%
|
|
Rajesh Krishnan
CTO/CSO |
72,992 | 28,973 | 44,019 $50,181 | 5 |
Jan 03, 2024
Reduced 21.19%
|
| 714 | 0 | 37,500 $42,749 | 1 |
Jun 16, 2022
Added 50.0%
|
|
| 10,000 | 980 | 10,000 $11,399 | 3 |
Apr 08, 2024
Added 23.58%
|